Connection

MANJUSHA GAGLANI to Aged, 80 and over

This is a "connection" page, showing publications MANJUSHA GAGLANI has written about Aged, 80 and over.
Connection Strength

0.421
  1. Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023. Influenza Other Respir Viruses. 2024 11; 18(11):e70027.
    View in: PubMed
    Score: 0.027
  2. Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022. J Infect Dis. 2024 Jul 25; 230(1):45-54.
    View in: PubMed
    Score: 0.027
  3. Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023. Influenza Other Respir Viruses. 2024 06; 18(6):e13342.
    View in: PubMed
    Score: 0.027
  4. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.023
  5. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(4):139-145.
    View in: PubMed
    Score: 0.023
  6. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.022
  7. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.022
  8. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 10 07; 385(15):1355-1371.
    View in: PubMed
    Score: 0.022
  9. Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019-2020. J Infect Dis. 2021 09 01; 224(5):813-820.
    View in: PubMed
    Score: 0.022
  10. Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network. J Infect Dis. 2021 07 02; 224(1):151-163.
    View in: PubMed
    Score: 0.022
  11. Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019. Vaccine. 2021 03 19; 39(12):1788-1796.
    View in: PubMed
    Score: 0.021
  12. Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. J Infect Dis. 2018 06 20; 218(2):189-196.
    View in: PubMed
    Score: 0.018
  13. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine. 2018 02 28; 36(10):1272-1278.
    View in: PubMed
    Score: 0.017
  14. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons. Vaccine. 2018 01 25; 36(4):467-472.
    View in: PubMed
    Score: 0.017
  15. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 10 01; 214(7):1010-9.
    View in: PubMed
    Score: 0.015
  16. Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013. Clin Infect Dis. 2016 Feb 15; 62(4):448-455.
    View in: PubMed
    Score: 0.015
  17. Factors associated with real-time RT-PCR cycle threshold values among medically attended influenza episodes. J Med Virol. 2016 Apr; 88(4):719-23.
    View in: PubMed
    Score: 0.015
  18. Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. Vaccine. 2015 Sep 22; 33(39):5181-7.
    View in: PubMed
    Score: 0.014
  19. Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season. Clin Infect Dis. 2015 Jun 01; 60(11):1677-80.
    View in: PubMed
    Score: 0.014
  20. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
    View in: PubMed
    Score: 0.014
  21. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. Clin Infect Dis. 2014 Sep 15; 59(6):774-82.
    View in: PubMed
    Score: 0.013
  22. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.